Medicines & supplements – Current GIS Alerts 2026
Found 734 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Corhydron 25
An out-of-specification (OOS) result was found in stability testing for the free hydrocortisone content; further increase is expected until the end of shelf life of batch 110021, which may affect dissolution and the drug’s performance. Potential effects: reduced therapeutic efficacy or unpredictable effects of the injectable medicine.
Symibace
An exceedance of the specification limit for impurity B was found, which according to the authority represents a real and probable risk to human health. Potential effects: poisoning, complications, lack of treatment safety.
Symibace
It was found that the specification limit for contamination (Impurity B) in batch 49N013A was exceeded, which means failure to meet established quality requirements and represents a real and probable risk to patients’ health. Potential effects: adverse reactions, treatment complications, possible deterioration of health.
Faringan
Non-compliance with quality requirements was found: too low benzocaine content, exceeding acceptable limits of related substances (including a single unknown impurity), and excessive tablet crumbling in the friability test. Potential effects: reduced treatment efficacy, possible undefined toxicological risk, difficulties in taking crumbled tablets.
Faringan
non-compliance was found consisting in exceeding the lower limit of benzocaine content, exceeding the permissible limit of benzocaine-related substances (single unknown impurity and total impurities), and crumbling of tablets after abrasion resistance testing. Potential effects: lack of treatment efficacy, unknown risk from impurities, possible adverse effects.
Eptifab
Incorrect information in the leaflet was found: swapped dosing instructions for patients with normal and impaired renal function, which may lead to improper dosing of the injection solution and direct, serious health consequences. Potential effects: poisoning, severe bleeding complications, lack of treatment efficacy, life‑threatening events.
Vabysmo
Cracked blisters with needles with a transfer filter were identified in product packs, so sterility of the needles and the solution for injection is not ensured; the defect was classified as Class I, potentially life‑threatening or posing a serious health risk. Potential effects: severe intraocular infections, ophthalmic complications, sepsis, life‑threatening condition.
Vabysmo
Cracked blisters with needles with transfer filter were found, so the sterility of the needles and the solution for injection is not ensured; a class I defect, potentially life‑threatening for patients. Potential effects: infection, severe ophthalmic complications, life‑threatening conditions.
Gripblocker Express
Cracking of the soft gelatin shell seams and leakage of the capsule fill into the blister pocket were found, creating a real risk to patients’ health through the possibility of taking an incomplete dose and lack of effectiveness of the medicinal product. Potencjalne skutki: lack of treatment effectiveness, worsening or prolongation of disease symptoms.
Gripblocker Express
The quality defect consists of cracking of the soft gelatin capsule seams and leakage of the filling into the blister pocket, creating a real risk to patients’ health due to the possibility of receiving an incomplete dose and lack of treatment effectiveness. Potential effects: lack of treatment efficacy, possible complications of the underlying disease.
Maść szałwiowa
The lack of a correct marketing authorisation number on the outer packaging makes it impossible to verify whether the product can be legally marketed in Poland and raises doubts about the authenticity of the medicine; it may mislead users, posing a threat to public health. Potential effects: inability to verify medicine authenticity, risk of using a product not compliant with its authorisation.
Maść szałwiowa
The lack of a correct authorization number on the packaging makes it impossible to verify if the product may be marketed in Poland and raises doubts about its authenticity. This situation may mislead users and poses a threat to public health. Potential effects: incorrect use of the medicine, lack of treatment efficacy, possible health complications.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content below the lower limit and, for one batch, non-compliant capsule mass uniformity, leading to a reduced dose of the medicine. Potential effects: reduced treatment efficacy, worsening of disease symptoms.
Konaten
for 7 of 41 batches marketed in Poland, out‑of‑specification results for atomoxetine content were found in reference samples, below the lower specification limit; the medical risk assessment indicated possible low effectiveness of the medicine. Potential effects: reduced therapeutic efficacy, risk of lack of the expected treatment effect.
Konaten
Out-of-specification (OOS) results were found in reference samples for atomoxetine content, below the lower specification limit; for one batch also non-compliance in capsule mass uniformity; the impact on safety was assessed as low. Potential effects: reduced treatment effectiveness, possible worsening of symptoms, risk of complications due to poor disease control.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content, below the lower specification limit, and in one batch also non-compliance in the mass uniformity parameter. The risk assessment points mainly to a possibility of reduced treatment effectiveness. Potential effects: absence or reduction of therapeutic efficacy.
Konaten
For some batches reference samples showed out-of-specification atomoxetine content below the lower limit, and for one batch also non-compliant capsule mass uniformity. Potential effects: reduced treatment efficacy, risk of lack of therapeutic effect.
Konaten
Out-of-specification results were found in reference samples for atomoxetine content (outside the 95.0–105.0% range) and, in one case, for capsule mass, indicating variable active substance dosage. Potential effects: reduced treatment effectiveness or increased adverse reactions.
Konaten
Out-of-specification (OOS) results were found for atomoxetine content (below the lower limit) and, for one batch, failure in capsule mass uniformity, which may lead to administration of too low a dose of the active substance. Potential effects: reduced treatment efficacy, possible worsening of disease symptoms.
Konaten
Out-of-specification results were found for atomoxetine content, below the lower specification limit, and for one batch non‑compliant capsule mass uniformity; the risk assessment indicated mainly potentially reduced drug efficacy. Potential effects: lack of or reduced treatment effectiveness.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.